WO2008155998A1 - Agent tranquillisant/antidépresseur - Google Patents
Agent tranquillisant/antidépresseur Download PDFInfo
- Publication number
- WO2008155998A1 WO2008155998A1 PCT/JP2008/060477 JP2008060477W WO2008155998A1 WO 2008155998 A1 WO2008155998 A1 WO 2008155998A1 JP 2008060477 W JP2008060477 W JP 2008060477W WO 2008155998 A1 WO2008155998 A1 WO 2008155998A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antianxiety
- antidepressant
- antidepressant agent
- activity
- agent
- Prior art date
Links
- 230000000049 anti-anxiety effect Effects 0.000 title abstract 7
- 239000000935 antidepressant agent Substances 0.000 title abstract 7
- 239000002249 anxiolytic agent Substances 0.000 title abstract 7
- 230000000694 effects Effects 0.000 abstract 3
- 230000001430 anti-depressive effect Effects 0.000 abstract 2
- 229940005513 antidepressants Drugs 0.000 abstract 2
- 235000013361 beverage Nutrition 0.000 abstract 2
- 235000013305 food Nutrition 0.000 abstract 2
- 235000020710 ginseng extract Nutrition 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La présente invention concerne : un agent tranquillisant/antidépresseur ayant un niveau satisfaisant d'activité tranquillisante et/ou d'activité antidépressive ; et un aliment ou une boisson comprenant l'agent tranquillisant/antidépresseur. L'invention concerne spécifiquement un agent tranquillisant/antidépresseur comprenant un extrait de ginseng fermenté et/ou un composant produit à partir de l'extrait de ginseng fermenté comme ingrédient actif. L'invention concerne également spécifiquement un aliment ou une boisson portant une notice mentionnant que cet aliment/boisson est utilisé(e) pour la prévention ou le traitement de l'anxiété ou de la dépression, qui est caractérisé par le fait qu'il(elle) comprend un agent tranquillisant/antidépresseur et présente une activité tranquillisante/antidépressive.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009520423A JPWO2008155998A1 (ja) | 2007-06-21 | 2008-06-06 | 抗不安抗うつ剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007164183 | 2007-06-21 | ||
JP2007164034 | 2007-06-21 | ||
JP2007-164183 | 2007-06-21 | ||
JP2007-164034 | 2007-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008155998A1 true WO2008155998A1 (fr) | 2008-12-24 |
Family
ID=40156157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/060477 WO2008155998A1 (fr) | 2007-06-21 | 2008-06-06 | Agent tranquillisant/antidépresseur |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2008155998A1 (fr) |
WO (1) | WO2008155998A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011121926A (ja) * | 2009-12-14 | 2011-06-23 | Lion Corp | プロトパナキサトリオール及びプロトパナキサジオール含有組成物 |
CN102145006A (zh) * | 2010-02-09 | 2011-08-10 | 张作光 | 人参皂甙Ppt的抗抑郁用途 |
JP2013529899A (ja) * | 2010-05-14 | 2013-07-25 | 株式会社ジーシーエイチアンドピー | ジンセノサイド成分を増加させた新規な加工人参または加工人参抽出物の製造方法 |
JP2015168614A (ja) * | 2014-03-04 | 2015-09-28 | 長瀬産業株式会社 | Glp−1分泌促進剤 |
JP2016508489A (ja) * | 2013-01-31 | 2016-03-22 | シャンハイ イノベーティブ リサーチ センター オブ トラディショナル チャイニーズ メディスン | プロトパナキサジオール誘導体、その製造方法及びその応用 |
KR101641509B1 (ko) * | 2015-01-22 | 2016-07-21 | 샘표 주식회사 | 아글리콘인 ppd 및/또는 ppt를 유효성분으로 포함하는 항스트레스용 조성물 |
JP6450878B1 (ja) * | 2018-03-28 | 2019-01-09 | 株式会社ナガセビューティケァ | 発酵物の製造方法 |
JP2019524835A (ja) * | 2016-08-16 | 2019-09-05 | エムディー ヘルスケア インコーポレイテッドMd Healthcare Inc. | ラクトバチルス属細菌由来小胞を含む精神疾患の予防または治療用組成物 |
US10709749B2 (en) | 2013-08-30 | 2020-07-14 | Green Cross Wellbeing Corporation | Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1099094A (ja) * | 1996-09-25 | 1998-04-21 | Happy World:Kk | 薬用ニンジンサポニン代謝産物の製造法 |
JP2004049154A (ja) * | 2002-07-23 | 2004-02-19 | Hideo Hasegawa | サポニン分解物を含む発酵人参およびその製造方法 |
JP2005160373A (ja) * | 2003-12-02 | 2005-06-23 | Hideo Hasegawa | 配糖体分解性プロバイオティクス |
JP2006508660A (ja) * | 2002-12-05 | 2006-03-16 | ホングリム トレーディング カンパニー リミテッド | 人参の乳酸菌発酵物、それを含有する人参ヨーグルト及びそれに利用される乳酸菌の菌株 |
JP2008000102A (ja) * | 2006-06-26 | 2008-01-10 | Bio Ken:Kk | ヨーグルト製造用種菌 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4773512B2 (ja) * | 2005-04-26 | 2011-09-14 | コ,ブン−キョン | 人参サポニンRg2の抽出方法及びその抽出物を含む医薬組成物とその用途 |
CN100438876C (zh) * | 2006-06-09 | 2008-12-03 | 上海中药创新研究中心 | 20(s)-原人参二醇在制备抗抑郁药物中的应用 |
-
2008
- 2008-06-06 WO PCT/JP2008/060477 patent/WO2008155998A1/fr active Application Filing
- 2008-06-06 JP JP2009520423A patent/JPWO2008155998A1/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1099094A (ja) * | 1996-09-25 | 1998-04-21 | Happy World:Kk | 薬用ニンジンサポニン代謝産物の製造法 |
JP2004049154A (ja) * | 2002-07-23 | 2004-02-19 | Hideo Hasegawa | サポニン分解物を含む発酵人参およびその製造方法 |
JP2006508660A (ja) * | 2002-12-05 | 2006-03-16 | ホングリム トレーディング カンパニー リミテッド | 人参の乳酸菌発酵物、それを含有する人参ヨーグルト及びそれに利用される乳酸菌の菌株 |
JP2005160373A (ja) * | 2003-12-02 | 2005-06-23 | Hideo Hasegawa | 配糖体分解性プロバイオティクス |
JP2008000102A (ja) * | 2006-06-26 | 2008-01-10 | Bio Ken:Kk | ヨーグルト製造用種菌 |
Non-Patent Citations (4)
Title |
---|
HASEGAWA H.: "Kanpo to Probiotic", IGAKU NO AYUMI, vol. 207, no. 10, 2003, pages 857 - 861 * |
PARK J.-H. ET AL.: "Anxiolytic-like effects of ginseng in the elevated plus-maze model: Comparison of red dinseng and sun ginseng", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY, vol. 29, no. 6, July 2005 (2005-07-01), pages 895 - 900 * |
TACHIKAWA E. ET AL.: "In vitro inhibition of adrenal catecholamine secretion by steroidal metabolites of ginseng saponins", BIOCHEMICAL PHARMACOLOGY, vol. 66, no. 11, 2003, pages 2213 - 2221 * |
WEI X.-Y. ET AL.: "Anxiolytic effect of saponins from Panax quinquefolium in mice", J. ETHNOPHARMACOL., vol. 111, no. 3, 22 May 2007 (2007-05-22), pages 613 - 618 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011121926A (ja) * | 2009-12-14 | 2011-06-23 | Lion Corp | プロトパナキサトリオール及びプロトパナキサジオール含有組成物 |
CN102145006A (zh) * | 2010-02-09 | 2011-08-10 | 张作光 | 人参皂甙Ppt的抗抑郁用途 |
JP2013529899A (ja) * | 2010-05-14 | 2013-07-25 | 株式会社ジーシーエイチアンドピー | ジンセノサイド成分を増加させた新規な加工人参または加工人参抽出物の製造方法 |
US9512453B2 (en) | 2010-05-14 | 2016-12-06 | Green Cross Wellbeing Corporation | Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased |
JP2016508489A (ja) * | 2013-01-31 | 2016-03-22 | シャンハイ イノベーティブ リサーチ センター オブ トラディショナル チャイニーズ メディスン | プロトパナキサジオール誘導体、その製造方法及びその応用 |
US10709749B2 (en) | 2013-08-30 | 2020-07-14 | Green Cross Wellbeing Corporation | Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent |
US11464821B2 (en) | 2013-08-30 | 2022-10-11 | Green Cross Wellbeing Corporation | Composition for reducing cancer cachexia or weight loss caused by anticancer drug therapy or radiation therapy comprising ginseng extract having increased ginsenoside Rg3 and Rh2 |
JP2015168614A (ja) * | 2014-03-04 | 2015-09-28 | 長瀬産業株式会社 | Glp−1分泌促進剤 |
KR101641509B1 (ko) * | 2015-01-22 | 2016-07-21 | 샘표 주식회사 | 아글리콘인 ppd 및/또는 ppt를 유효성분으로 포함하는 항스트레스용 조성물 |
JP2019524835A (ja) * | 2016-08-16 | 2019-09-05 | エムディー ヘルスケア インコーポレイテッドMd Healthcare Inc. | ラクトバチルス属細菌由来小胞を含む精神疾患の予防または治療用組成物 |
EP3501527A4 (fr) * | 2016-08-16 | 2020-05-06 | MD Healthcare Inc. | Composition permettant de prévenir ou de traiter un trouble mental, contenant une vésicule dérivée de bactéries d'une espècelactobacillus |
US11583559B2 (en) | 2016-08-16 | 2023-02-21 | Md Healthcare Inc. | Composition for preventing or treating mental disorder, containing Lactobacillus sp. bacteria-derived vesicle |
JP2019170246A (ja) * | 2018-03-28 | 2019-10-10 | 株式会社ナガセビューティケァ | 発酵物の製造方法 |
JP6450878B1 (ja) * | 2018-03-28 | 2019-01-09 | 株式会社ナガセビューティケァ | 発酵物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008155998A1 (ja) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008155998A1 (fr) | Agent tranquillisant/antidépresseur | |
WO2008023266A3 (fr) | Extrait de kiwi | |
WO2006096434A3 (fr) | Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete | |
WO2006096439A3 (fr) | Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees | |
WO2007093624A3 (fr) | Nouvelles compositions pharmaceutiques pour le traitement du trouble d'hyperactivité avec déficit de l'attention | |
WO2009078447A1 (fr) | Agent contre les norovirus, agent contre le virus de la grippe et procédé de traitement antiviral utilisant chacun de ces agents | |
WO2007061661A3 (fr) | Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1 | |
WO2008155999A1 (fr) | Activateur des neurones gabaergiques | |
WO2007087250A3 (fr) | Inhibiteurs tricycliques de la 5-lipoxygenase | |
WO2011090270A3 (fr) | Composition contenant de l'osmotine pour prévenir et traiter des troubles neurologiques | |
WO2005094235A3 (fr) | Flocons de soja grillés et leur procédé de fabrication | |
WO2009089263A3 (fr) | Nouvelles compositions et procédés d'utilisation | |
WO2007038506A3 (fr) | Methode de traitement de la cachexie | |
WO2010058926A3 (fr) | Composition pharmaceutique contenant un extrait de gingembre ou du shogaol | |
WO2009060952A1 (fr) | Nouvelle préparation | |
WO2008048121A3 (fr) | Composés et compositions | |
WO2009036204A3 (fr) | Activité antioxydante et de détoxification de phase ii | |
WO2009051223A1 (fr) | Composition pharmaceutique pour le traitement de la cataracte | |
WO2009091120A3 (fr) | Composition renfermant des extraits de lindera obtusiloba pour la prévention et le traitement de maladies cardio-vasculaires | |
WO2008019782A3 (fr) | Dispersions d'agents contenant des nanoparticules d'urée | |
WO2008126367A1 (fr) | Agent neuroleptique et aliment fonctionnel | |
SG153840A1 (en) | Novel compound having inhibitory effect on lipase | |
WO2009091121A3 (fr) | Composition renfermant des extraits de lysimachia clethroides pour la prévention et le traitement de maladies cardio-vasculaires | |
WO2008094054A3 (fr) | Composés | |
WO2012081831A3 (fr) | Composition comprenant un extrait de loranthus yadoriki sieb. ayant une activité inhibitrice sur la monoamine oxydase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08765290 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009520423 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08765290 Country of ref document: EP Kind code of ref document: A1 |